Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did Not Compromise Efficacy in Asian Patients with Stage III Colon Cancer
Findings from the phase III ACHIEVE study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer
It is indicated for the treatment of patients who have received a prior anti-HER2-based regimen
EMA Recommends Extension of Therapeutic Indications for Pembrolizumab
New indication concerns a neoadjuvant and adjuvant treatment of adult patients with triple negative breast cancer at high risk of recurrence
Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar High-Grade Squamous Intraepithelial Lesions
Findings from a randomised, phase III, non-inferiority study
EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in Patients with Resectable NSCLC
Higher percentage of patients with a pathological complete response also achieved with neoadjuvant nivolumab plus chemotherapy
Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival in De Novo Metastatic Castration-Sensitive Prostate Cancer
Findings from the PEACE-1 study
EMA Recommends Extension of Therapeutic Indications for Cabozantinib
New indication concerns the treatment of patients with differentiated thyroid carcinoma refractory or not eligible to radioactive iodine
Increased Risk of Cancer in Early Life Among Individuals with Autism Spectrum Disorders
Increased cancer risk among individuals with autism is likely attributable to co-occurring intellectual disability and/or birth defects
FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Evidence for efficacy is based on the results from the ZUMA-7 study
Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with Newly Diagnosed IDH1-Mutated AML
Findings from a phase III, AGILE study in patients with newly diagnosed IDH1-mutated acute myeloid leukaemia ineligible for induction chemotherapy
Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Findings from final prespecified overall survival analysis and an update on radiographic progression-free survival in the ARCHES study